MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure

R. Dreicer, W. M. Stadler, F. R. Ahmann, T. Whiteside, N. Bizouarne, B. Acres, J. M. Limacher, P. Squiban, A. Pantuck

Research output: Contribution to journalArticlepeer-review

56 Scopus citations

Fingerprint

Dive into the research topics of 'MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure'. Together they form a unique fingerprint.

Medicine & Life Sciences